3SBio Inc. (01530.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 16.06

From 52W high−54.19%

Volume15.99M

Market capHKD 38.16B

P/E (TTM)4.1x

P/S (TTM)1.8x

Div yield1.59%

Key dataSep 18, 2026

Open

HKD 16.06

From 52W high

−54.19%

Volume

15.99M

Market cap

HKD 38.16B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.7x

P/E (TTM)

4.1x

RSI (14)

42.4

MomentumView details →

1D Return

−1.44%

YTD Return

−34.86%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

4.1x

EV/EBITDA

1.7x

EV/Sales

1.1x

P/S (TTM)

1.8x

P/B (TTM)

1.2x

ProfitabilityView details →

Gross Margin

91.97%

Net Margin

46.37%

EBITDA Margin

64.02%

ROE (TTM)

30.00%

ROA (TTM)

23.21%

Asset Turnover

0.50x

GrowthView details →

Revenue YoY

+96.21%

EPS YoY

+238.78%

FCF YoY

+254.94%

Revenue CAGR 3Y

+37.15%

EPS CAGR 3Y

+63.83%

EBITDA YoY

+323.79%

MomentumView details →

1D Return

−1.44%

YTD Return

−34.86%

1Y Return

−48.26%

RSI (14)

42.4

vs 50D SMA

−6.96%

vs 200D SMA

−25.63%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

6.06x

Quick Ratio

5.75x

Div Yield

1.59%

Div Rate

HKD 0.25

Div Growth 1Y

+0.00%

EarningsView details →

EPS (Actual)

HKD 0.51

EPS Surprise

−31.26%

Beats (12Q)

0/12

Next Q EPS Est

—

Avg Surprise (4Q)

−31.26%

Rev Surprise

−3.41%

Financials snapshotView financials →

Revenue (TTM)

26.88B

Net Income (TTM)

10.61B

Op. CF (TTM)

—

Next earningsMar 30, 2027 →

Latest newsMore news →

3SBio Inc. announced its interim results for the six months ended June 2026, with net profit of RMB 1.147 billion, down 15.6% year-on-year.31d ago

Several Chinese public funds, including E Fund, China Asset Management, Fullgoal Fund, and China Universal Fund, increased their holdings in Hong Kong-listed biotech stocks, triggering the 5% disclosure threshold for Baioct-B, 3SBio, CSPC Pharmaceutical Group, Kelun-Biotech, and H&H International Holdings.61d ago

Similar companies

三生国健688336.SH Oncocross Co., Ltd.382150.KQ IMBdx461030.KQ 君实生物-U688180.SH Revolution Medicines, Inc.RVMD 万泰生物603392.SH Find similar companies →

Latest newsMore news →

3SBio Inc. announced its interim results for the six months ended June 2026, with net profit of RMB 1.147 billion, down 15.6% year-on-year.31d ago Several Chinese public funds, including E Fund, China Asset Management, Fullgoal Fund, and China Universal Fund, increased their holdings in Hong Kong-listed biotech stocks, triggering the 5% disclosure threshold for Baioct-B, 3SBio, CSPC Pharmaceutical Group, Kelun-Biotech, and H&H International Holdings.61d ago